Blog
RSS FeedPosted by Michael Wonder on 18 Jan 2018
Early benefit assessments: the 220th dossier evaluation completed at the turn of the year
18 January 2018 - Oncology remains by far the most common indication. ...
Posted by Michael Wonder on 16 Jan 2018
In a nutshell 2017: new issue with facts and graphics from the IQWiG
15 January 2018 - Third issue with focus on quality assurance/numerous graphs illustrate work results. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
Posted by Michael Wonder on 15 Jan 2018
German watchdog calls for direct comparison of cancer immunotherapies
16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...
Posted by Michael Wonder on 09 Jan 2018
Finding RCTs of new drugs: searches in trial registries require specific adaptations
5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...
Posted by Michael Wonder on 03 Sep 2017
Nivolumab in squamous cell carcinoma in the head and neck area: additional benefit for certain patients
1 September 2017 - Significant benefit for patients with progression during or shortly after platinum-based therapy. ...
Posted by Michael Wonder on 03 Jul 2017
IQWiG finds no additional benefit for tenofovir alafenamide fumarate in chronic hepatitis B
3 July 2017 - The anti-viral medicine tenofovir alafenamide fumarate has been used in various combinations since 2015 in HIV ...
Posted by Michael Wonder on 01 Jun 2017
Secukinumab and ixekizumab in psoriasis: significant additional benefit for certain patients
1 June 2017 - The manufacturer of secukinumab has applied for a new benefit assessment as new scientific evidence emerges. ...
Posted by Michael Wonder on 16 May 2017
Pembrolizumab in non-small-cell lung cancer: a hint of considerable added benefit
15 May 2017 - Patients in the relevant subpopulation of the analysed study survived longer. ...
Posted by Michael Wonder on 25 Apr 2017
IQWiG in Dialogue 2017: programme is now online
24 April 2017 - The first IQWiG methods paper (version 1.0) was published on March 1, 2005. Since then the IQWiG ...
Posted by Michael Wonder on 13 Apr 2017
Clinuvel reaches agreement on German Scenesse pricing through AMNOG Arbitration Board
12 April 2017 - Clinuvel today announced that it had reached agreement with the German National Association of Statutory Health ...
Posted by Michael Wonder on 29 Mar 2017
German Federal Joint Committee (G-BA) confirms additional benefit of anti-cancer agent Kisplyx (lenvatinib mesylate) in treatment of advanced renal cell carcinoma
28 March 2017 - Eisai announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house ...
Posted by Michael Wonder on 12 Mar 2017
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
12 March 2017 - This study determined methodological requirements for health-related quality of life measurement and data presentation in the early ...
Posted by Michael Wonder on 08 Mar 2017
Germany to scrap plan to lower prices of new drugs-lawmakers
6 March 2017 - Germany's ruling coalition will scrap plans announced last year to lower prices of newly launched drugs ...
Posted by Michael Wonder on 01 Mar 2017
Palbociclib in advanced breast cancer: disadvantages in certain patients
1 March 2017 - More frequent severe side effects in first-line therapy after menopause/missing data for other patients. ...